Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $140.4 million.

  • Ironwood Pharmaceuticals' Cash & Equivalents rose 5917.18% to $140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $140.4 million, marking a year-over-year increase of 5917.18%. This contributed to the annual value of $88.6 million for FY2024, which is 390.11% down from last year.
  • According to the latest figures from Q3 2025, Ironwood Pharmaceuticals' Cash & Equivalents is $140.4 million, which was up 5917.18% from $92.9 million recorded in Q2 2025.
  • Ironwood Pharmaceuticals' Cash & Equivalents' 5-year high stood at $740.3 million during Q1 2023, with a 5-year trough of $88.2 million in Q3 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' median Cash & Equivalents value was $175.3 million (recorded in 2023), while the average stood at $332.5 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Cash & Equivalents surged by 9454.89% in 2021 and then tumbled by 8595.65% in 2023.
  • Over the past 5 years, Ironwood Pharmaceuticals' Cash & Equivalents (Quarter) stood at $620.1 million in 2021, then rose by 5.82% to $656.2 million in 2022, then crashed by 85.96% to $92.2 million in 2023, then decreased by 3.9% to $88.6 million in 2024, then soared by 58.55% to $140.4 million in 2025.
  • Its Cash & Equivalents was $140.4 million in Q3 2025, compared to $92.9 million in Q2 2025 and $108.5 million in Q1 2025.